A Double-Masked, Randomized, Placebo-Controlled Dose Escalation Study of the Safety and Tolerability of P 321 Ophthalmic Solution in Subjects With Dry Eye Disease
Phase of Trial: Phase I/II
Latest Information Update: 01 May 2017
At a glance
- Drugs SHP-659 (Primary)
- Indications Dry eyes
- Focus Adverse reactions; Therapeutic Use
- Sponsors Parion Sciences
- 01 May 2017 Results published in a Shire media release.
- 03 May 2016 Results will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2016 meeting, according to a Parion Sciences media release.
- 30 Apr 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.